1. Medtech Insight
  2. >>Device Area

Market Intel: Market Dynamics Switchover To Come In Fast-Growing Soft Tissue Fixation Segment

 
• By Marion Webb

Global sales for arthroscopy and sports medicine devices are predicted to hit $6.5bn by 2021. This will be driven by the fast-growing soft tissue fixation products segment: significant changes in market dynamics are expected over the next few years, as hip fixation procedures pick up pace. This article delves into the landscape of the soft tissue fixation device market, as well as the four key segments in the arthroscopy devices space. It will also analyze the key players in these markets, highlight trends and discuss the biggest challenges.

Arthroscopy_1200x675

Global sales for arthroscopy and sports medicine devices are expected to reach $6.5bn by 2021, representing a CAGR of 4.1%. Of the two main market segments, soft tissue fixation products and arthroscopy devices, soft tissue fixation represented the smaller segment with 35.7% market share in 2016 vs. 64.3% for arthroscopy devices. However, it will see the most significant growth over the next few years.

According to a new report by Meddevicetracker, "Global Market for Arthroscopy and Sports Medicine Devices", worldwide sales of soft tissue fixation devices totaled about $1.9bn in 2016 and are expected to achieve a CAGR of 6% during the five-year forecast period, double the expected growth rate for arthroscopy products

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Orthopedics

More from Device Area

First At-Home Cervical Cancer Screening Tool Gets FDA Clearance

 
• By Elizabeth Orr

The US FDA has approved the Teal Wand, the first at-home cervical cancer screening device. Capable of detecting preclinical cancer with 96% accuracy, it will launch in California in June and expand nationwide soon after.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By Marion Webb

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 
• By Natasha Barrow

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”